Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Bayer's patent for blood thinner Xarelto invalid, UK court rules

Published 12/04/2024, 15:27
Updated 12/04/2024, 19:40
© Reuters. FILE PHOTO: The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023.
BAYGN
-

LONDON (Reuters) - Bayer (ETR:BAYGN)'s patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.

The company's blockbuster Xarelto drug generated nearly $4.1 billion in revenue in 2023, according to research firm Statista.

Bayer's attempts to replace Xarelto were thrown into doubt last year when it aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy.

Its European patent over once-daily rivaroxaban, with a brand name of Xarelto, has now been declared invalid following legal challenges brought by Sandoz (SIX:SDZ) and other rival manufacturers.

Judge Richard Hacon said Bayer's patent was invalid because of the lack of an "inventive step" in developing the drug.

Friday's decision paves the way for other drug makers to launch generic versions of rivaroxaban, though Bayer said it would be seeking to block such attempts pending any appeal.

"We are seeking permission to appeal this decision and seeking interim injunctive relief to prevent the launch of 10mg, 15mg and 20mg generic rivaroxaban products," a Bayer spokesperson said in a statement.

© Reuters. FILE PHOTO: The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park

"We believe in the validity of our patent as confirmed by the decision of the European Patent Office in 2021 and we continue to be committed to protecting our intellectual property."

Sandoz did not immediately respond to a request for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.